Φορτώνει......
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed markedly. Although sorafenib was used in clinical practice as the first molecular targeted agent in 2007, the SHARPE and Asian-Pacific trials demonstrated that sorafenib only improved overall survival (OS) by approxim...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Exp Clin Cancer Res |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6827249/ https://ncbi.nlm.nih.gov/pubmed/31684985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1412-8 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|